NEW YORK (GenomeWeb News) – OncoMethylome Sciences said today that it is collaborating with Merck KGaA to use its MGMT gene promoter methylation technology to select patients for trials for drugs to treat glioblastoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.